Hormonal
SGLT-2 inhibitors (empagliflozin, canagliflozin, dapagliflozin) reduce cardiovascular death and heart failure hospitalizations in patients with type 2 diabetes, heart failure, or chronic kidney disease, regardless of baseline glycemic control.
If you have heart failure, kidney disease, or high-risk diabetes, ask your doctor about SGLT-2 inhibitors (like Jardiance, Farxiga, or Invokana). These drugs protect your heart and kidneys, not just your blood sugar. The benefits are proven to reduce hospital stays and death, even if your blood sugar is already well-controlled.
The SGLT-2 inhibitors canagliflozin, dapagliflozin, and empagliflozin reduced rates of cardiovascular death and hospitalization for worsening heart failure.
Why this rating
Based on multiple large-scale Phase 3 CVOTs (EMPA-REG, DAPA-HF, CREDENCE, DAPA-CKD) with statistically significant results.
Source
Obesity 2021: Current Clinical Management of a Chronic, Serious Disease
Kushner · The Journal of Family Practice · 2021
DOI 10.12788/jfp.0221
More from this paper
- SGLT-2 inhibitors slow the progression of chronic kidney disease (CKD) and reduce the risk of end-stage kidney disease (ESKD) in patients with type 2 diabetes and albuminuria.Strong
- SGLT-2 inhibitors reduce the risk of worsening heart failure and cardiovascular death in patients with heart failure with reduced ejection fraction (HFrEF), regardless of diabetes status.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →